{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-047099","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.294806+00:00","generated_at":"2026-05-30T01:28:45.098446+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sangamo posts Q3 net income $10.7M; FDA clears Accelerated Approval path for Fabry gene therapy ST-920","bullets":["Net income $10.7M ($0.04 diluted EPS) vs net loss $104.2M ($0.59 loss) in Q3 2023.","Revenue $49.4M (up from $9.4M), driven by $49.2M from Genentech collaboration.","FDA agrees Phase 1/2 STAAR data can support Accelerated Approval for ST-920 in Fabry disease; BLA submission expected H2 2025.","Received $50M from Genentech upfront/milestones; eligible for up to $1.9B in additional milestones plus tiered royalties.","Cash $39.2M; expects to fund operations into Q1 2025 including $10M milestone from Genentech."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-047099","json":"https://secwatch.observer/filing/0001628280-24-047099.json","markdown":"https://secwatch.observer/filing/0001628280-24-047099.md","text":"https://secwatch.observer/filing/0001628280-24-047099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024047099/0001628280-24-047099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024047099/sgmo-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:28:45.098446+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}